Quick Answer
HeartSciences Inc. reported R&D Expense of $4.39 million for fiscal year 2025.
HeartSciences Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $4.39M | +52.4% |
| 2024 | $2.88M | +17.0% |
| 2023 | $2.46M | -18.0% |
| 2022 | $3.00M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| January 31, 2026 | $638.6K | -38.2% | -12.2% |
| October 31, 2025 | $727.0K | -39.4% | -27.1% |
| July 31, 2025 | $997.2K | -18.6% | -3.5% |
| January 31, 2025 | $1.03M | +102.8% | -13.8% |
| October 31, 2024 | $1.20M | +58.3% | -2.1% |
| July 31, 2024 | $1.22M | +116.6% | +140.4% |
| January 31, 2024 | $509.5K | -20.8% | -32.7% |
| October 31, 2023 | $757.3K | -10.8% | +33.9% |
- HeartSciences Inc. showed an increase of +52.4% in R&D Expense compared to the prior fiscal year.
- Over the 2022–2025 period, HeartSciences Inc.’s r&d expense has grown by 46.1% (from $3.00 million to $4.39 million).
- The most recent figure is from HeartSciences Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on July 24, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: